Compare AU & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AU | BIO |
|---|---|---|
| Founded | 1944 | 1952 |
| Country | United States | United States |
| Employees | N/A | 7450 |
| Industry | Precious Metals | Biotechnology: Laboratory Analytical Instruments |
| Sector | Basic Materials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.2B | 6.9B |
| IPO Year | 2023 | N/A |
| Metric | AU | BIO |
|---|---|---|
| Price | $83.85 | $293.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | $119.00 | ★ $339.75 |
| AVG Volume (30 Days) | ★ 1.9M | 405.9K |
| Earning Date | 05-08-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.94% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $38.71 | $2.74 |
| Revenue Next Year | $2.89 | $3.20 |
| P/E Ratio | $23.93 | ★ $9.72 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.34 | $219.94 |
| 52 Week High | $129.14 | $343.12 |
| Indicator | AU | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 36.72 | 52.60 |
| Support Level | $80.83 | $262.08 |
| Resistance Level | $88.90 | $314.39 |
| Average True Range (ATR) | 3.51 | 10.37 |
| MACD | -0.73 | 1.65 |
| Stochastic Oscillator | 0.46 | 46.32 |
Anglogold Ashanti PLC is one of the gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from the Africa region which includes its operations of the Kibali, Iduapriem, Obuasi, Siguiri, and Geita mines.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.